| 13.8 -0.5 (-3.5%) | 11-19 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 17.05 | 1-year : | 19.91 |
| Resists | First : | 14.6 | Second : | 17.05 |
| Pivot price | 13.99  |
|||
| Supports | First : | 12.8 | Second : | 11.69 |
| MAs | MA(5) : | 14.26 |
MA(20) : | 13.73 |
| MA(100) : | 12.73 |
MA(250) : | 12.83 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 60.9 |
D(3) : | 76.2 |
| RSI | RSI(14): 54.7 |
|||
| 52-week | High : | 15.85 | Low : | 10.14 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ FNCH ] has closed above bottom band by 37.5%. Bollinger Bands are 34.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 14.04 - 14.11 | 14.11 - 14.17 |
| Low: | 13.36 - 13.45 | 13.45 - 13.53 |
| Close: | 13.64 - 13.78 | 13.78 - 13.91 |
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
Thu, 06 Feb 2025
Finch Therapeutics: Post-Trial Decision Can Potentially Drive Shares To Trade Higher - Seeking Alpha
Mon, 21 Oct 2024
Finch Announces Delisting from Nasdaq and SEC Deregistration - GlobeNewswire
Mon, 05 Sep 2022
Finch Therapeutics Group, Inc. (FNCH) Upgraded to Buy: Here's Why - Nasdaq
Sun, 17 Oct 2021
Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation - Nasdaq
Tue, 05 Oct 2021
Finch Therapeutics Appoints Samuel Allen Hamood to its Board of Directors - citybiz
Tue, 27 Apr 2021
Finch Therapeutics Appoints Susan E. Graf to Board of Directors - citybiz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 53.4 (%) |
| Held by Institutions | 4.6 (%) |
| Shares Short | 19 (K) |
| Shares Short P.Month | 11 (K) |
| EPS | -8.81 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.85 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -21.9 % |
| Return on Equity (ttm) | -67.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -12.12 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -18 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -1.57 |
| PEG Ratio | 0 |
| Price to Book value | 1.55 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.24 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|